Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 6/20 | 0.61 |
| ▸ | CTSC | P53634 | 3/20 | 0.57 |
| ▸ | EGFR | P00533 | 6/20 | 0.51 |
| ▸ | ITK | Q08881 | 4/20 | 0.51 |
| ▸ | BRD4 | O60885 | 2/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL305410 | 0.86 | SYK (0.59) | SYKEGFRITKBRD4JAK3 | |
| SCHEMBL14390054 | 0.86 | SYK (0.58) | SYKCTSCEGFRITKBRD4 | |
| SCHEMBL13072638 | 0.86 | SYK (0.58) | SYKCTSCEGFRITKBRD4 | |
| SCHEMBL270210 | 0.85 | SYK (0.63) | SYKCTSCEGFRITKBRD4 | |
| SCHEMBL301912 | 0.83 | CTSC (0.57) | SYKCTSCITKBTK | |
| SCHEMBL12111163 | 0.79 | BRD4 (0.59) | SYKCTSCEGFRITKBRD4 | |
| SCHEMBL12321383 | 0.79 | SYK (0.55) | SYKEGFRITKBTKJAK3 | |
| SCHEMBL305045 | 0.79 | SYK (0.78) | SYKEGFRITKBTKJAK3 | |
| SCHEMBL301484 | 0.78 | EGFR (0.57) | SYKEGFRITKBTKJAK3 | |
| SCHEMBL12518349 | 0.78 | EGFR (0.81) | SYKEGFRITKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951684-B1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | IMPACT BIOMEDICINES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | SYK 281/4885CTSC 3323/4885EGFR 181/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | SYK 281/4885CTSC 3323/4885EGFR 181/4885 |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, JAK3 | SYK 281/4885CTSC 3323/4885EGFR 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.